Ironwood Pharmaceuticals, Inc.IRWDNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -19.47% | -22.98% | -45.05% | -9.70% | +33.26% |
| Gross Profit Growth | -45.45% | -22.98% | -72.05% | -9.70% | +97.62% |
| EBITDA Growth | -35.44% | -17.61% | -184.13% | +73.71% | +181.84% |
| Operating Income Growth | -47.26% | -16.22% | -364.14% | +81.45% | +194.45% |
| Net Income Growth | -76.20% | +0.00% | +0.00% | +0.00% | +999.29% |
| EPS Growth | -76.81% | +0.00% | +0.00% | +0.00% | +996.49% |
| EPS Diluted Growth | -72.20% | +0.00% | +0.00% | +0.00% | +908.77% |
| Weighted Average Shares Growth | +2.45% | +2.49% | +2.08% | +1.70% | +1.57% |
| Weighted Average Shares Diluted Growth | -14.26% | +2.82% | +2.08% | +1.70% | +10.94% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -69.55% | -57.54% | -55.64% | -145.03% | +381.37% |
| Free Cash Flow Growth | -69.55% | -57.29% | -55.64% | -145.11% | +382.13% |
| Receivables Growth | -38.82% | -36.58% | -44.78% | +48.30% | +57.96% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -25.67% | -25.51% | -25.43% | -13.31% | +1.68% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | -16.98% | -16.22% | -13.23% | -6.50% | -2.70% |
| R&D Expense Growth | -7.59% | -28.83% | +6.26% | -23.08% | -24.67% |
| SG&A Expenses Growth | +11.65% | -13.13% | +0.00% | -54.56% | -39.33% |